Femasys (NASDAQ:FEMY) Trading 4.5% Higher

Femasys Inc. (NASDAQ:FEMY)’s stock price traded up 4.5% during trading on Friday . The company traded as high as $1.32 and last traded at $1.29. 62,294 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 590,263 shares. The stock had previously closed at $1.24.

Wall Street Analysts Forecast Growth

FEMY has been the topic of several research reports. Chardan Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Femasys in a report on Monday, April 1st. HC Wainwright boosted their price objective on Femasys from $10.00 to $12.00 and gave the company a “buy” rating in a report on Monday, April 1st. Finally, Jonestrading upped their target price on Femasys from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th.

Femasys Trading Up 4.5 %

The company has a quick ratio of 7.37, a current ratio of 7.59 and a debt-to-equity ratio of 0.24. The firm has a 50 day moving average price of $1.61 and a 200 day moving average price of $1.23. The stock has a market capitalization of $28.51 million, a PE ratio of -1.40 and a beta of -2.76.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.30 million. Femasys had a negative return on equity of 105.47% and a negative net margin of 1,329.10%. Equities analysts expect that Femasys Inc. will post -0.88 EPS for the current fiscal year.

Institutional Trading of Femasys

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Femasys in the 3rd quarter worth about $35,000. Wealthspire Advisors LLC purchased a new position in Femasys in the third quarter valued at about $84,000. Barclays PLC bought a new position in shares of Femasys during the 3rd quarter valued at approximately $295,000. Finally, Clear Creek Financial Management LLC increased its stake in shares of Femasys by 30.6% during the 1st quarter. Clear Creek Financial Management LLC now owns 309,274 shares of the company’s stock worth $479,000 after purchasing an additional 72,505 shares during the last quarter. 65.27% of the stock is owned by hedge funds and other institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.